Distal Versus Proximal Intracoronary Drug Delivery for the Treatment of the No-Reflow Phenomenon During Percutaneous Coronary Intervention
Journal of Clinical Medicine · 13.08.2026 · 15 (16) · 6252
DOI: 10.3390/jcm15166252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.08.2026. Verfasst von Umeyir Savur und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Istanbul Medipol University, Medipol Mega University Hospital, 34214 Istanbul, Türkiye. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: The optimal intracoronary drug delivery strategy for the management of the no-reflow phenomenon (NRP) during percutaneous coronary intervention (PCI) remains uncertain. We compared distal and proximal intracoronary drug administration for the treatment of NRP.
Methods
This retrospective single-center study included 212 consecutive patients who developed NRP following drug-eluting stent implantation between January 2022 and June 2025. Patients were treated with intracoronary medications administered either proximally through the guiding catheter (n = 107) or distally using a microcatheter or guide extension catheter (n = 105). The primary outcome was the restoration of final Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow. Multivariable logistic regression with bootstrap internal validation was performed.
Results
Despite a higher prevalence of baseline TIMI 0 flow (85.7% vs. 19.6%, p < 0.001) and higher SYNTAX scores in the distal group, distal drug administration achieved a higher rate of final TIMI grade 3 flow (66.7% vs. 27.1%, p < 0.001) and final TIMI grade 2–3 flow (90.5% vs. 73.8%, p = 0.003). Distal administration remained an independent predictor of final TIMI grade 3 flow (adjusted OR 15.94, 95% CI 5.22–48.69; p < 0.001), with consistent findings in a sensitivity analysis accounting for adjunctive intracoronary pharmacological therapy. The optimism-corrected area under the receiver operating characteristic curve was 0.707. No significant between-group differences were observed in in-hospital or 6-month clinical outcomes.
Conclusions
Distal intracoronary drug administration was associated with a higher likelihood of achieving TIMI grade 3 flow than conventional proximal administration. These findings should be considered hypothesis-generating and require confirmation in prospective randomized studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Istanbul Medipol University, Medipol Mega University Hospital, 34214 Istanbul, Türkiye.
ORCID-Profile: Umeyir Savur, Berhan Keskin, Irem Koc, Yerkenur Khidolda, Atakan Dursun, Aysel Akhundova, Aykun Hakgor, Haci Murat Gunes, Bilal Boztosun
Zitieren
APA
Savur, U., Keskin, B., Koc, I., Khidolda, Y., Dursun, A., Akhundova, A., Hakgor, A., Gunes, H. M., & Boztosun, B. (2026). Distal Versus Proximal Intracoronary Drug Delivery for the Treatment of the No-Reflow Phenomenon During Percutaneous Coronary Intervention. Journal of Clinical Medicine, 15(16), 6252. https://doi.org/10.3390/jcm15166252
Vancouver
Savur U, Keskin B, Koc I, Khidolda Y, Dursun A, Akhundova A, et al. Distal Versus Proximal Intracoronary Drug Delivery for the Treatment of the No-Reflow Phenomenon During Percutaneous Coronary Intervention. Journal of Clinical Medicine. 2026;15(16):6252. doi:10.3390/jcm15166252
BibTeX
@article{Savur2026,
author = {Savur, Umeyir and Keskin, Berhan and Koc, Irem and Khidolda, Yerkenur and Dursun, Atakan and Akhundova, Aysel and Hakgor, Aykun and Gunes, Haci Murat and Boztosun, Bilal},
title = {Distal Versus Proximal Intracoronary Drug Delivery for the Treatment of the No-Reflow Phenomenon During Percutaneous Coronary Intervention},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {16},
pages = {6252},
doi = {10.3390/jcm15166252}
}
EUVIMED